TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCTS LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 SECONDARY SOURCES
2.10 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 CLINICAL TRIALS
4.2 RECENT DEVELOPMENTS
4.3 BRAND COMPETITIVE ANALYSIS
4.4 SUPPLY CHAIN ANALYSIS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISING INCIDENCES OF INBORN ERRORS OF METABOLISM
5.1.2 PREFERENCE OF DIETARY SUPPLEMENTS OVER ENZYME REPLACEMENT THERAPY
5.1.3 GOVERNMENT INITIATIVES AND PROGRAMS FOR CREATING AWARENESS ABOUT IEM
5.1.4 INCREASE IN THE NUMBER OF NEW BORN SCREENING PROCEDURES
5.2 RESTRAINTS
5.2.1 INADEQUATE REIMBURSEMENT SCENARIO
5.2.2 STRINGENT REGULATIONS FOR MEDICAL FOODS
5.2.3 HIGH COST OF MEDICAL FOODS
5.3 OPPORTUNITIES
5.3.1 INNOVATIVE PRODUCT LAUNCHES FOR NEW INDICATIONS
5.3.2 INCREASING SPENDING ON MEDICAL FOODS PRODUCTS
5.4 CHALLENGES
5.4.1 PRODUCT RECALLS
5.4.2 POOR ACCESSIBILITY OF MEDICAL FOODS
6 COVID-19 IMPACT ANALYSIS
7 MIDDLE EAST & AFRICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS
7.1 OVERVIEW
7.2 AMINO ACID
7.2.1 SINGLE AMINO ACID
7.2.1.1 L-ARGININE
7.2.1.2 L-ISOLEUCINE
7.2.1.3 L-TYROSINE
7.2.1.4 L-LEUCINE
7.2.1.5 GLYCINE
7.2.1.6 OTHERS
7.2.2 AMINO ACID MIXTURES
7.2.2.1 PHENYLADE
7.2.2.1.1 DRINK MIX
7.2.2.1.2 GMP MIX-IN
7.2.2.1.3 GMP READY
7.2.2.1.4 OTHERS
7.2.2.2 PERIFLEX
7.2.2.3 LOPHLEX
7.2.2.4 PHLEXY
7.2.2.5 COOLER
7.2.2.6 ANAMIX
7.2.2.7 LYSINE-FREE, LOW TRYPTOPHAN
7.2.2.8 GLUTARADE ESSENTIAL GA-1
7.2.2.9 GLUTARADE GA-1 AMINO ACID BLEND
7.2.2.10 GLYTACTIN WITH GMP
7.2.2.11 OTHERS
7.3 LOW PROTEIN FOOD
7.4 GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON
7.5 LOW-CALCIUM/VITAMIN D-FREE INFANT FORMULA WITH IRON
7.6 OTHERS
8 MIDDLE EAST & AFRICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY AGE GROUP
8.1 OVERVIEW
8.2 INFANTS
8.3 WEANING
8.4 ADOLESCENT
8.5 ADULTS
9 MIDDLE EAST & AFRICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES
9.1 OVERVIEW
9.2 PHENYLKETONURIA (PKU)
9.2.1 PHENYLADE
9.2.2 PERIFLEX
9.2.3 LOPHLEX
9.2.4 OTHERS
9.3 TYROSINEMIA TYPES I AND II
9.4 MAPLE SYRUP URINE DISEASE (MSUD)
9.4.1 ANAMIX
9.4.2 COOLER
9.4.3 MSUD GEL
9.4.4 AMINO ACID BLEND
9.4.5 MAXMUM
9.4.6 OTHERS
9.5 HOMOCYSTINURIA
9.6 GLUTARIC ACIDEMIA TYPE I
9.7 UREA CYCLE DISORDERS
9.8 METHYLMALONIC ACIDEMIA
9.9 ISOVALERIC ACIDEMIA
9.10 ORGANIC ACIDURIAS
9.11 RENAL DISEASE
9.12 PROPIONIC ACIDEMIA
9.13 DISORDERS OF LEUCINE METABOLISM
9.14 OTHERS
10 MIDDLE EAST & AFRICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY FORM
10.1 OVERVIEW
10.2 POWDER
10.3 LIQUID
10.4 OTHERS
11 MIDDLE EAST & AFRICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PACKAGING
11.1 OVERVIEW
11.2 CAN
11.3 PACKET
11.4 BOTTLE
11.5 JAR
11.6 OTHERS
12 MIDDLE EAST & AFRICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 RETAIL PHARMACIES
12.3 HOSPITAL PHARMACIES
12.4 DRUGS STORES
12.5 ONLINE PHARMACIES
12.6 OTHERS
13 MIDDLE EAST & AFRICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION
13.1 MIDDLE EAST & AFRICA
13.1.1 SOUTH AFRICA
13.1.2 SAUDI ARABIA
13.1.3 OMAN
13.1.4 REST OF MIDDLE EAST & AFRICA
14 MIDDLE EAST & AFRICA MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
15 COMPANY PROFILE
15.1 ABBOTT
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENT
15.2 BIOMARIN
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.3 MEAD JOHNSON & COMPANY, LLC. (A SUBSIDIARY OF RECKITT BENCKISER GROUP PLC.)
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENT
15.4 NESTLe HEALTH SCIENCE (A SUBSIDIARY OF NESTLe)
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENT
15.5 AJINOMOTO CAMBROOKE, INC. (A SUBSIDIARY OF AJINOMOTO CO., INC.)
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENTS
15.6 APR
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENT
15.7 DR. SCHaR AG / SPA
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENT
15.8 ENER-G FOODS, INC.
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.9 NUTRICIA (A SUBSIDIARY OF DANONE)
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENT
15.10 PKU-MDMIL
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.11 POA PHARMA
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENTS
15.12 PRISTINE ORGANICS PRIVATE LIMITED
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENT
15.13 PROMIN METABOLICS
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 SOLACE NUTRITION
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
16 SWOT & DATA BRIDGE MARKET RESEARCH ANALYSIS
16.1 SWOT ANALYSIS
16.1.1 STRENGTH: - STRONG PRODUCT PORTFOLIO
16.1.2 WEAKNESS: - NO INITIATIVES FOR EXPANSION
16.1.3 OPPORTUNITY: - INCREASING INVESTMENT IN RESEARCH AND DEVELOPMENT
16.1.4 THREAT: - STIFF COMPETITION
16.2 DATA BRIDGE MARKET RESEARCH ANALYSIS
17 CONCLUSION
18 QUESTIONNAIRE
19 RELATED REPORTS